ArticleBMC infectious diseases2026
Development and validation of a modified PAGE-B score based nomogram for predicting hepatocellular carcinoma in antiviral-treated chronic hepatitis B patients with metabolic dysfunction.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to construct and validate a nomogram to predict the long-term incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) and metabolic dysfunction (MD) receiving antiviral therapy.
methods809 individuals with hepatitis B combined with metabolic dysfunction who received antiviral therapy between 2009 and 2023 were randomly assigned to the training and validation cohorts in a 6:4 ratio using simple randomization performed with the sample function in R software (version 4.3.2). Independent risk factors for HCC were identified by Cox regression analysis, and a nomogram was subsequently constructed. The model’s performance was evaluated using calibration curves, decision curve analysis (DCA), and the area under the receiver operating characteristic curve (AUC).
resultsIndependent predictors of HCC development identified by multivariate Cox regression included lymphocyte count, the Triglyceride-Glucose index, and the modified PAGE-B score. These were incorporated into a nomogram with a total score range of 0 to 200 for risk prediction. The nomogram yielded a 3-year AUC of 0.828, numerically higher than established scores; however, DeLong tests confirmed no statistically significant superiority. Using the nomogram for risk stratification, the 5-year cumulative HCC incidence in the derivation cohort was 2.5% in the low-risk, 9.7% in the medium-risk, and 20.0% in the high-risk group. The validation cohort showed corresponding incidence rates of 0.8%, 12.7%, and 18.5%.
conclusionOur nomogram demonstrated favorable discriminative ability and calibration accuracy for predicting HCC risk among antiviral-treated patients with CHB and MD. Patients stratified into the high-risk group (scores > 151) could be prioritized for intensified surveillance, highlighting the model’s utility in risk-stratified clinical management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.